Back to resultsRepeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study (ZYL-730-02)
Primary Purpose
Treatment Resistant Major Depressive Disorder
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Almond Therapy
Intranasal ketamine (Esketamine)
Treatment as Usual
Sponsored by
About this trial
This is an interventional treatment trial for Treatment Resistant Major Depressive Disorder
Eligibility Criteria
Inclusion Criteria:
- Participants must have completed Study ZYL-730-01 through to Day 28
- Adults aged 18-64
- Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent.
- Women must use a medically acceptable reliable means of contraception and must agree to use adequate birth control for the duration of the study and for 6 weeks after the last dose using methods from the permitted list for contraception.
- If currently receiving medication for depression their antidepressant dose(s) must be stable for the previous 4 weeks prior to baseline.
- Must be on a stable dose of all other medication(s) for at least 1-month prior to baseline visit., unless medication is to treat other short term conditions (i.e. influenza, upper respiratory track infections, pain, etc.)
- Controlled hypertension and must be on a stable dose of antihypertensive medications for at least 3 months prior to the baseline visit.
Exclusion Criteria:
- Women who plan to become pregnant, are pregnant or are breastfeeding.
- Serious unstable medical illness, or any significant change in medical status at the baseline visit and during the study, as determined by the Investigator
- Hormonal treatment (e.g., Estrogen) started within the 3 months prior to first dose of study treatment.
- Participants who report treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) at the baseline visit and within 2 weeks prior to the first dose of Esketamine .
- Participants with confirmed psychotic disorder or symptoms, bipolar disorder and or clinically significant alcohol or substance misuse confirmed by a psychiatrist at the baseline visit. Those participants who develop symptoms of these may be withdrawn from the study, as determined by the Investigator
- Current diagnosis of bulimia nervosa, or development of significant eating disorder symptoms at the baseline visit or during the study as determined by the Investigator
- Participants who have been diagnosed with ADD/ADHD and who are also currently taking stimulant medication such as methylphenidate or another amphetamine-type medication, or who are diagnosed with this disorder or who start medication for this during the study.
- Participants currently taking St John's Wort, Ginseng or Turmeric who start any of these during the study
- Participants judged clinically to be actively at serious risk of self-harm or suicidal behaviour by the study team or psychiatrist at baseline or at any time during the study, as determined by the Investigator.
- Blood pressure >140/90 at baseline
- Participants who are unable to easily travel to the clinic for all of the in-person visits.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Intranasal Esketamine with Addition of Almond TherapyTM
Intranasal Esketamine with Treatment as Usual
Arm Description
Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
Outcomes
Primary Outcome Measures
Change in Montgomery Asberg Depression Rating Scale (MADRS)
The MADRS is a clinician rated 10-item scale where individuals score from 0-6 based on the severity of their symptoms with higher scores indicative of greater severity
Secondary Outcome Measures
Change in Post-Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (PCL-5
A 20-item self-administered measure that assesses the presence and severity of PTSD symptoms derived from the symptoms of PTSD in DSM-5. Participants will be asked to rate how bothered they have been by each item in the 4 weeks on a 5-point Likert scale ranging from (0=Not at all to 4=Extremely). The PCL-5 is easily scored by summing all of the items for a total symptom severity score ranging between 0-80. Clinically meaningful PTSD symptoms are present if items are rated as a minimum of 2 = "Moderate" or higher.
Change in Patient Health Questionnaire (PHQ-9)
A 9-item self-administered questionnaire to determine the presence and severity of depression which scores each of the 9 DSM-IV criteria as "0"(not at all), to "3" (nearly everyday
Change in Generalized Anxiety Disorder Questionnaire (GAD-7)
A 7-item self-administered questionnaire to measure the severity of the levels of anxiety. Each item can be scored 0-3, giving a total score of 0-21.
Change in Rosenberg Self-Esteem Questionnaire (RSES)
A 10-item self administered questionnaire to measure change in self esteem following psychological intervention. Each item scoring from 1-4, and higher scores indication greater self-esteem
Change in Quality of Life 8 Dimensional Questionnaire (AQoL-8D)
Self administered questionnaire measuring quality of life across 8 domains: independent living, happiness, mental health, coping, relationships, self-worth, pain and senses
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05438758
Brief Title
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
Acronym
ZYL-730-02
Official Title
Phase 2, Controlled, Single-Blind, 3-Month Extension Study For Participants Originally Diagnosed With Treatment Resistant Major Depressive Disorder (TRD) Who Complete Study ZYL-730-01 With, or Without, Almond Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Withdrawn by Sponsor
Study Start Date
January 15, 2023 (Anticipated)
Primary Completion Date
February 1, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zylorion Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
Detailed Description
The duration of the study is 3 months
Participants enrolled in the Almond Therapy group will have up to 9 in person visits, including the baseline visits, participants will receive Esketamine on 8 of these visits. There are 12 remote therapy sessions conducted via telephone or video, participants will also receive supportive text messages. In addition, participants will have 4 telephone calls from an independent assessor to ask questions about their mental health (MADRS).
Participants enrolled in the Treatment as Usual group will have up to 9 in person visits, including the baseline visits, participants will receive Esketamine on 8 of these visits. Participants will continue to receive the therapy their treating physician felt was appropriate at the time of enrolment in the study. In addition, participants will have 4 telephone calls from an independent assessor to ask questions about their mental health (MADRS).
Participants will receive intranasal Esketamine 56mg or 84 mg once weekly for 4 weeks and 56 mg or 84 mg once every 2 weeks for 8 weeks as per Product Monograph
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment Resistant Major Depressive Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants who have received Almond Therapy in study ZYL-730-01 will continue to have this in the extension study Participants who received Treatment as Usual in study ZYL-730-02 will continue to have this in the extension study.
Masking
Outcomes Assessor
Masking Description
The independent trained individual will not be aware of which treatment arm the participant is in. The Montgomery Asberg Depression Rating Scale (MADRS) assessor will have no other contact with participant apart from remotely assessing the MADRS
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intranasal Esketamine with Addition of Almond TherapyTM
Arm Type
Other
Arm Description
Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
Arm Title
Intranasal Esketamine with Treatment as Usual
Arm Type
Other
Arm Description
Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Almond Therapy
Intervention Description
Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
Intervention Type
Drug
Intervention Name(s)
Intranasal ketamine (Esketamine)
Intervention Description
Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
Intervention Type
Behavioral
Intervention Name(s)
Treatment as Usual
Intervention Description
Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
Primary Outcome Measure Information:
Title
Change in Montgomery Asberg Depression Rating Scale (MADRS)
Description
The MADRS is a clinician rated 10-item scale where individuals score from 0-6 based on the severity of their symptoms with higher scores indicative of greater severity
Time Frame
Baseline, Day 26, 54 and 89
Secondary Outcome Measure Information:
Title
Change in Post-Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders (PCL-5
Description
A 20-item self-administered measure that assesses the presence and severity of PTSD symptoms derived from the symptoms of PTSD in DSM-5. Participants will be asked to rate how bothered they have been by each item in the 4 weeks on a 5-point Likert scale ranging from (0=Not at all to 4=Extremely). The PCL-5 is easily scored by summing all of the items for a total symptom severity score ranging between 0-80. Clinically meaningful PTSD symptoms are present if items are rated as a minimum of 2 = "Moderate" or higher.
Time Frame
Baseline, Day 26, 54 and 82
Title
Change in Patient Health Questionnaire (PHQ-9)
Description
A 9-item self-administered questionnaire to determine the presence and severity of depression which scores each of the 9 DSM-IV criteria as "0"(not at all), to "3" (nearly everyday
Time Frame
Baseline, Day 12, 26, 40, 54, 68 and 82
Title
Change in Generalized Anxiety Disorder Questionnaire (GAD-7)
Description
A 7-item self-administered questionnaire to measure the severity of the levels of anxiety. Each item can be scored 0-3, giving a total score of 0-21.
Time Frame
Baseline, Day 12, 26, 40, 54, 68 and 82
Title
Change in Rosenberg Self-Esteem Questionnaire (RSES)
Description
A 10-item self administered questionnaire to measure change in self esteem following psychological intervention. Each item scoring from 1-4, and higher scores indication greater self-esteem
Time Frame
Baseline, Day 26, 54 and 82
Title
Change in Quality of Life 8 Dimensional Questionnaire (AQoL-8D)
Description
Self administered questionnaire measuring quality of life across 8 domains: independent living, happiness, mental health, coping, relationships, self-worth, pain and senses
Time Frame
Baseline, Day 26, 54 and 82
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants must have completed Study ZYL-730-01 through to Day 28
Adults aged 18-64
Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent.
Women must use a medically acceptable reliable means of contraception and must agree to use adequate birth control for the duration of the study and for 6 weeks after the last dose using methods from the permitted list for contraception.
If currently receiving medication for depression their antidepressant dose(s) must be stable for the previous 4 weeks prior to baseline.
Must be on a stable dose of all other medication(s) for at least 1-month prior to baseline visit., unless medication is to treat other short term conditions (i.e. influenza, upper respiratory track infections, pain, etc.)
Controlled hypertension and must be on a stable dose of antihypertensive medications for at least 3 months prior to the baseline visit.
Exclusion Criteria:
Women who plan to become pregnant, are pregnant or are breastfeeding.
Serious unstable medical illness, or any significant change in medical status at the baseline visit and during the study, as determined by the Investigator
Hormonal treatment (e.g., Estrogen) started within the 3 months prior to first dose of study treatment.
Participants who report treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) at the baseline visit and within 2 weeks prior to the first dose of Esketamine .
Participants with confirmed psychotic disorder or symptoms, bipolar disorder and or clinically significant alcohol or substance misuse confirmed by a psychiatrist at the baseline visit. Those participants who develop symptoms of these may be withdrawn from the study, as determined by the Investigator
Current diagnosis of bulimia nervosa, or development of significant eating disorder symptoms at the baseline visit or during the study as determined by the Investigator
Participants who have been diagnosed with ADD/ADHD and who are also currently taking stimulant medication such as methylphenidate or another amphetamine-type medication, or who are diagnosed with this disorder or who start medication for this during the study.
Participants currently taking St John's Wort, Ginseng or Turmeric who start any of these during the study
Participants judged clinically to be actively at serious risk of self-harm or suicidal behaviour by the study team or psychiatrist at baseline or at any time during the study, as determined by the Investigator.
Blood pressure >140/90 at baseline
Participants who are unable to easily travel to the clinic for all of the in-person visits.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre Chue, MBBCh
Organizational Affiliation
Amygdala Associates Inc.
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be available to other members of the study team including Dr. Craig Buchholz
IPD Sharing Time Frame
Throughout the study
IPD Sharing Access Criteria
Involved in data collection
Learn more about this trial
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
We'll reach out to this number within 24 hrs